-+ 0.00%
-+ 0.00%
-+ 0.00%

GT Biopharma Initiated Dosing In Cohort 3 Of Its Phase 1 Dose Escalation Trial Of GTB-3650 For Relapsed Or Refractory CD33 Expressing Hematologic Malignancies, Plans On Releasing Initial Phase 1 Results Later In 2025 Following Completion Of Additional Dose Cohorts

Benzinga·08/11/2025 11:14:02
Listen to the news
  • The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observed.
  • The company plans on releasing initial Phase 1 results later in 2025 following completion of additional dose cohorts